Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of temsirolimus when given with
imatinib mesylate in treating patients with chronic myelogenous leukemia. Drugs used in
chemotherapy, such as temsirolimus, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Imatinib mesylate may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving temsirolimus with imatinib mesylate may kill more cancer cells